Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Companyâs drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Companyâs operations are principally based in North America, Europe, and Asia.
äŒæ¥ã³ãŒãMEDP
äŒç€ŸåMedpace Holdings Inc
äžå Žæ¥Aug 11, 2016
æé«çµå¶è²¬ä»»è
ãCEOãTroendle (August J)
åŸæ¥å¡æ°5900
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Aug 11
æ¬ç€Ÿæåšå°5375 Medpace Way
éœåžCINCINNATI
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·45227-1543
é»è©±çªå·15135799911
ãŠã§ããµã€ãhttps://investor.medpace.com/
äŒæ¥ã³ãŒãMEDP
äžå Žæ¥Aug 11, 2016
æé«çµå¶è²¬ä»»è
ãCEOãTroendle (August J)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã